Presentations by Event

Presented at ASM Microbe, Boston, June 2016

ETX2514, a Novel, Rationally Designed Inhibitor of Class A, C and D β–lactamases, for the Treatment of Gram-negative Infections

Adam Shapiro, ASM Microbe 2016

Program(s): durlobactam (etx2514)

A Phase II Trial of Single-Dose Oral ETX0914 (AZD0914) for Treatment of Uncomplicated Urogenital Gonorrhea

Ken Lawrence, ASM Microbe 2016

Addressing the Evolving Challenge of β-lactamase Mediated Antimicrobial Resistance: ETX2514, a Next-generation BLI with Potent, Broad Spectrum Activity Against Class A, C & D Enzymes

Ruben Tommasi, ASM Microbe 2016

Program(s): durlobactam (etx2514)

In Vitro and In Vivo Efficacy of the Novel β-lactamase Inhibitor ETX2514 Combined with Sulbactam Against Multidrug Resistant Acinetobacter baumannii

John O’Donnell, ASM Microbe 2016

Program(s): durlobactam (etx2514)

Presented at The Boston Area Antimicrobial Research Network, Cambridge, June 2016

Challenges and Opportunities in Drug Discovery

Alita Miller, Boston Area Antimicrobial Research Network 2016

Presented at The Applied Pharmaceutical Chemistry meeting, Boston, April 2016

Improving our Understanding of Porin Permeability in Gram-negative Bacteria

Thomas Durand-Reville, Applied Pharmaceutical Chemistry Meeting 2016